文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

临床观察到的HIV整合酶突变组合对整合酶链转移抑制剂表型耐药的影响:一项分子研究

Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究构建携带所有突变组合的重组NL4.3病毒,在0.01-1000 nM拉替拉韦、埃替拉韦、多替拉韦、比替拉韦和卡博特韦存在下测定表型易感性。结果显示高水平的整合酶链转移抑制剂(INSTI)耐药需要多个整合酶替换包括补偿性突变,T97A和E138K进一步增强G140S/Q148H所 conferred的耐药,四突变共存时对所有INSTI的敏感性降低>300倍。

要点

  • 缺乏G140S的Q148H病毒无法传播或在体外发生突变,提示适合度代价。
  • G140S/Q148H消除拉替拉韦和埃替拉韦活性,并降低多替拉韦、比替拉韦和卡博特韦敏感性。
  • T97A/E138K/G140S/Q148H在自体骨架中对所有INSTI敏感性降低>300倍。

核心结论

  • 高水平的整合酶链转移抑制剂(INSTI)耐药需要多个整合酶替换包括补偿性突变。
  • T97A和E138K进一步增强G140S/Q148H所 conferred的耐药,四突变共存时对所有INSTI的敏感性降低>300倍。
  • 比替拉韦EC50在T97A/E138K/G140S/Q148H引入NL4.3时显著降低,提示自体序列中其他突变增强了耐药。

研究设计与样本

  • 构建携带自体整合酶序列中所有突变组合的重组NL4.3病毒。
  • 病毒在表达GFP报告基因的CD4+ T细胞中于0.01-1000 nM拉替拉韦、埃替拉韦、多替拉韦、比替拉韦和卡博特韦存在下培养。
  • 通过成像细胞术测量感染。

主要发现

  • 缺乏G140S的Q148H病毒无法传播或在体外发生突变,与适合度代价一致。
  • T97A或G140S单独导致对拉替拉韦和埃替拉韦敏感性降低3.6至5.6倍。
  • 双突变组合仅对拉替拉韦和埃替拉韦产生低至中度耐药,除外G140S/Q148H消除拉替拉韦和埃替拉韦活性并对多替拉韦、比替拉韦和卡博特韦分别降低敏感性24.6倍、7.9倍和107.5倍。
  • 在G140S/Q148H基础上加入E138K导致对多替拉韦、比替拉韦和卡博特韦敏感性分别降低35.5倍、11.6倍和208倍;加入T97A则分别降低318倍、121倍和>1000倍。
  • 自体骨架中T97A/E138K/G140S/Q148H对所有INSTI敏感性降低>300倍;比替拉韦EC50在T97A/E138K/G140S/Q148H引入NL4.3时显著降低,提示自体序列中其他突变增强了耐药。

关键数值与推荐

  • T97A或G140S单独:对拉替拉韦和埃替拉韦敏感性降低3.6至5.6倍。
  • G140S/Q148H:对多替拉韦、比替拉韦和卡博特韦敏感性分别降低24.6倍、7.9倍和107.5倍。
  • G140S/Q148H/E138K:对多替拉韦、比替拉韦和卡博特韦敏感性分别降低35.5倍、11.6倍和208倍。
  • G140S/Q148H/T97A:对多替拉韦、比替拉韦和卡博特韦敏感性分别降低318倍、121倍和>1000倍。
  • T97A/E138K/G140S/Q148H:对所有INSTI敏感性降低>300倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine HIV drug resistance genotyping identified an integrase sequence harbouring T97A, E138K, G140S and Q148H, with high predicted resistance to all integrase strand transfer inhibitors (INSTIs). OBJECTIVES: To assess the impact of these substitutions alone and together on phenotypic INSTI susceptibility. METHODS: We constructed recombinant NL4.3 viruses harbouring all mutation combinations in the autologous integrase sequence. Viruses were grown in GFP-reporter CD4+ T-cells in the presence of 0.01-1000 nM raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir. Infection was measured by imaging cytometry. RESULTS: Q148H-containing viruses lacking G140S failed to propagate or mutated in vitro, consistent with fitness costs. Statistically significant reductions in INSTI susceptibility were observed for several mutation combinations, as follows. T97A or G140S alone conferred 3.6- to 5.6-fold decreased susceptibility to raltegravir and elvitegravir. Two-mutation combinations conferred low-to-moderate resistance to raltegravir and elvitegravir only, except G140S/Q148H which eliminated raltegravir and elvitegravir activity and conferred 24.6-, 7.9-, and 107.5-fold reduced susceptibility to dolutegravir, bictegravir and cabotegravir. Addition of E138K to G140S/Q148H conferred 35.5, 11.6 and 208-fold reduced susceptibility to dolutegravir, bictegravir, and cabotegravir, while addition of T97A to G140S/Q148H conferred 318, 121 and >1000-fold reduced susceptibility to these drugs. T97A/E138K/G140S/Q148H in the autologous backbone conferred >300-fold reduced susceptibility to all INSTIs. Notably, bictegravir EC50 was significantly lower when T97A/E138K/G140S/Q148H was introduced into NL4.3, suggesting that other mutations in the autologous sequence enhanced resistance. CONCLUSIONS: High-level dolutegravir, bictegravir and cabotegravir resistance requires multiple integrase substitutions including compensatory mutations. T97A and E138K further enhance the resistance conferred by G140S/Q148H, yielding >300-fold decreased susceptibility to all INSTIs when all four mutations are present.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cheung PK, Shahid A, Dong W, et al. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. J Antimicrob Chemother. 2022. PMID: 35061879. doi:10.1093/jac/dkab498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。